Mariana Oncology, a Novartis company, is a Watertown, Massachusetts biotechnology company developing precision radioligand therapies (RLTs) — targeted radiopharmaceuticals that deliver alpha- and beta-emitting radioisotopes selectively to tumor cells while sparing healthy tissue. Its pipeline pursues solid-tumor targets including DLL3-expressing small cell lung cancer (MC-339), alongside breast and prostate programs, and it operates a Radioligand Therapy Innovation Center of Excellence for radiochemistry, isotope handling and clinical supply. Founded in 2020 and acquired by Novartis in May 2024, Mariana Oncology is a therapeutics developer, not a software vendor: it publishes no developer program, no public API, and no machine-readable interface of any kind.
Mariana Oncology is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Radiopharmaceuticals.
Mariana Oncology’s developer surface includes engineering blog and 9 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: mariana-oncology
name: Mariana Oncology
description: 'Mariana Oncology, a Novartis company, is a Watertown, Massachusetts biotechnology company developing precision
radioligand therapies (RLTs) — targeted radiopharmaceuticals that deliver alpha- and beta-emitting radioisotopes selectively
to tumor cells while sparing healthy tissue. Its pipeline pursues solid-tumor targets including DLL3-expressing small cell
lung cancer (MC-339), alongside breast and prostate programs, and it operates a Radioligand Therapy Innovation Center of
Excellence for radiochemistry, isotope handling and clinical supply. Founded in 2020 and acquired by Novartis in May 2024,
Mariana Oncology is a therapeutics developer, not a software vendor: it publishes no developer program, no public API, and
no machine-readable interface of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/mariana-oncology/refs/heads/main/apis.yml
deliveryModel:
model: saas
open_source: false
commercial: true
callable_host: false
label: Hosted service · you call their endpoint
confidence: medium
source:
- pricing
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
image: https://marianaoncology.com/mariana-og-image.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-25'
modified: '2026-08-25'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Radiopharmaceuticals
- Radioligand Therapy
- Life Sciences
- Healthcare
- Clinical Research
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/mariana-oncology-domain-security.yml
- type: Website
url: https://marianaoncology.com/
- type: Blog
url: https://marianaoncology.com/news/
- type: Contact
url: https://marianaoncology.com/contact/
- type: TermsOfService
url: https://marianaoncology.com/terms-of-use/
- type: PrivacyPolicy
url: https://marianaoncology.com/privacy-statement/
- type: LinkedIn
url: https://www.linkedin.com/company/marianaoncology
- type: ParentCompany
name: Novartis AG
url: https://www.novartis.com/
- type: ParentCompanyProfile
name: Novartis in the API Evangelist Network
url: https://github.com/api-evangelist/novartis
- type: AcquisitionAnnouncement
name: Mariana Oncology to be Acquired by Novartis
url: https://marianaoncology.com/news/mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/
x-enrichment:
date: '2026-08-25'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Mariana Oncology, a Novartis company, is a preclinical-stage radioligand-therapy developer whose entire web presence
is a 23-URL Gatsby marketing site (sitemap-0.xml) with no developer, docs or API section; api./developer./docs./portal.marianaoncology.com
are NXDOMAIN, there is no GitHub organization under any spelling of the name, and every contract-discovery path on the
one live host returns the site's 404 shell.
evidence:
- url: https://marianaoncology.com/openapi.json
status: 404
- url: https://marianaoncology.com/.well-known/agent-card.json
status: 404
- url: https://marianaoncology.com/graphql
status: 404
- url: https://marianaoncology.com/sitemap-0.xml
status: 200
- url: https://api.github.com/orgs/mariana-oncology
status: 404
checked: '2026-08-25'